AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04067102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide
Description: Paclitaxel 175mg/m2, I.v., d1； Carboplatin injection AUC 5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment protocol by the researcher
Study NCT04499313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Injectable solution
Study NCT01217307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500mg twice daily during 4 months
Study NCT01217307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily during 4 months
Study NCT02353169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT02353169 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Study NCT00436553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin Photodynamic Therapy
Description: After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 (Standard Fluence rate) or 25 J/cm\^2 (Reduced Fluence rate) to the study eye, begun 15 minutes after the start of the infusion.
Study NCT00436553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab 0.5 mg administered as an intravitreal injection.
Study NCT00436553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab 0.5 mg administered as an intravitreal injection.
Study NCT00436553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verteporfin Placebo
Description: To maintain masking, as a placebo for verteporfin photodynamic therapy, patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.
Study NCT00436553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab Placebo
Description: To maintain masking, patients in the combination groups received sham intravitreal injections whenever retreatment with active Ranibizumab was not warranted based on the retreatment algorithm.
Study NCT01826383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active-Video
Description: This group will watch an active-video with pain management strategies for parents
Study NCT01826383 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Video
Description: This group will watch a placebo-video describing immunization generally.
Study NCT01488630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STaRS
Description: The intervention entails testing an automated substance abuse treatment referral system (STaRS) to be implemented in primary care practices through electronic health record systems to improve 1) referral rates to specialty care providers, 2) patient treatment initiation with the specialty care providers, and 3) revenues to the practices.
Study NCT02175706 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Integrity®
Description: Biolinx-zotarolimus coating on a chobalt-cromium alloy stent platform that has a novel sinusoidal design.
Study NCT02175706 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Promus Element®
Description: fluoropolymer-everolimus coating on a novel stent platform made from a platinum-chromium alloy
Study NCT02609464 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interrupted Knotted Sutures
Study NCT02609464 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: STRATAFIX Symmetric PDS PLUS Knotless Tissue Control Devices
Study NCT04829227 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sofwave
Description: The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
Study NCT03194412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet /nutritional
Description: • Duration:~* the first stage - 3 months: 12 weeks~* second stage - 3 months: 12 weeks~Each patient collect a detailed menu of the last two days before making the description. Then the menu is analyzed by a nutrition consultant. The role of nutrition consultant is:~* make a diet modification to include the products recommended in frailty~* modifying eating habits~The diet modification is mainly focused on adequate supply:~* vitamin D (according to Central Europe guidelines -2013 for seniors)~* protein (according to European Society for Clinical Nutrition and Metabolism (ESPEN recommendations)
Study NCT03194412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: * Duration:~  * the first stage - 3 months: 12 weeks~ * second stage - 3 months: 12 weeks~* Frequency: twice a week~* Duration of each session: 60 minutes~Worksheets for the elderly with frailty syndrome have been developed:~* resistance exercises and strength training, which aim to improve muscle strength in the limbs~* exercises aimed at improving motor coordination, flexibility and speed~* stretching exercises.
Study NCT03194412 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Comprehensive therapy
Description: Combination of special diet for elderly (as in Group 1) and regular physical activity into everyday life of the elderly (as in Group 2)~Duration:~* the first stage - 3 months- 12 weeks~* the second stage - 3 months- 12 weeks Frequency of physical activity: twice a week Duration of each session: 60 minutes
Study NCT03194412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregivers of elderly
Description: Group: formal and informal caregivers of elderly with frailty syndrome Materials and Tools: multimedia presentation about frailty prevention and treatment (nutrition, physical activity, dietary supplement diet).~Duration:~* the first stage - 3 months: 12 weeks~* the second stage - 3 months: 12 weeks~Frequency: 1 (at the beginning of stage 0, 1 and 2) Duration: 60 minutes
Study NCT01522664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEDN6526A
Description: Multiple ascending doses
Study NCT00877032 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RN6G
Description: intravenous, single dose, dose ranging from 0.3mg/kg up to a maximum of 40 mg/kg.
Study NCT00877032 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous, single dose with experimental dose.
Study NCT01823965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Study NCT01122485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PG201
Description: two tablets
Study NCT01122485 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two tablets
Study NCT01269801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: onabotulinumtoxinA
Description: * Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;~* Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.~At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment.
Study NCT01269801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JUVÉDERM
Description: Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;~• Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.~At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment.
Study NCT01453556 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic right colectomy
Description: Laparoscopic right colectomy with mechanical ileo-colon anastomosis L-L
Study NCT01453556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic right colectomy
Description: Laparoscopic right colectomy with mechanical ileo-colon anastomosis L-L
Study NCT02726230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ananya
Description: The Ananya program was developed and implemented via a partnership of the Bill and Melinda Gates Foundation and the Government of Bihar as a means of improving reproductive, maternal, newborn and child health (RMNCH) outcomes in the state, in particular focusing on improving health behaviors and service utilization in the final trimester of pregnancy and early postpartum period. Ananya was designed as a series of supply- and demand-side efforts to improve health. Efforts were focused on strengthening outreach services in quantity and quality, improving quality of facility services, and mobilizing communities to improve health behaviors. The Ananya program included training, mobilizing, and monitoring of government frontline health workers (FLWs, including anganwadi workers- AWWS, auxiliary nurse midwives- ANMs, and community health workers-ASHAs) to increase quantity and quality of home visits for RMNH screenings and services, and media messages to increase demand for services.
Study NCT01205295 — intervention group
Intervention type: OTHER
Intervention: Cognitive behavioural therapy
Description: Cognitive behavioural therapy Psychologist Preoperative Efficacy of treatment
Study NCT01283932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole Sodium
Description: Pantoprazole Sodium DR Tablets 40 mg
Study NCT01283932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole Sodium
Description: Pantoprazole Sodium DR Tablets 40 mg
Study NCT00888511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: Tarceva 150 mg/day
Study NCT00888511 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 66 Gy/33 F/5 F per week for 5 weeks
Study NCT01561651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Occlusion
Description: Surgeon will occlude the left atrial appendage using a suture and/or a surgical stapler or a regulatory approved atrial appendage closure during the patient's cardiac surgery procedure.
Study NCT00434525 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic restrictive procedure
Description: Patients will receive laparoscopic sleeve gastrectomy with or without omentectomy
Study NCT00434525 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve gastrectomy
Description: Sleeve gastrectomy
Study NCT00217919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health-Counselor Mediated Telephone Counseling Intervention
Description: A trained health counselor will conduct the TC sessions, which will occur every 6 weeks (total 8 calls). We expect the initial call to last 30 minutes, with subsequent calls lasting 20 minutes. Our intervention for our primary outcome of LDL-C lowering is expected to take most of this time. We will spend approximately 5 minutes addressing physical activity at the end of each session, using methods similar to those in our pilot TC study.~We will use patient-centered counseling to promote adherence to lipid-lowering medication and LDL-C lowering diet. The intervention will also activate patients to discuss initiation or dose increase of lipid-lowering drugs with their physicians. While the focus of our intervention will be on LDL-C lowering, the TC intervention will also devote approximately 5 minutes of the typical 20 minute call to increasing physical activity.
Study NCT03710447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT + WB-EMS
Description: 12-week supervised exercise program consisting of ergometer-based high-intensity interval training (HIIT) and whole-body electromyostimulation (WB-EMS).~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. WB-EMS: Simulanteous stimulation of all major muscle groups with dedicated individual intensity.~2 exercise sessions per week. Order of application: HIIT - WB-EMS. Additionally, participants receive individualized nutritional counseling.
Study NCT03710447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WB-EMS + HIIT
Description: 12-week supervised exercise program consisting of whole-body electromyostimulation (WB-EMS) and ergometer-based high-intensity interval training (HIIT).~WB-EMS: Simulanteous stimulation of all major muscle groups with dedicated individual intensity.~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. 2 exercise sessions per week. Order of application: WB-EMS - HIIT. Additionally, participants receive individualized nutritional counseling.
Study NCT03710447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT + CST
Description: 12-week supervised exercise program consisting of ergometer-based high-intensity interval training (HIIT) and conventional low-volume strength training(CST).~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. CST: Conventional 1-set strength training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum.~2 exercise sessions per week. Order of application: HIIT - CST. Additionally, participants receive individualized nutritional counseling.
Study NCT03710447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CST + HIIT
Description: 12-week supervised exercise program consisting of conventional low-volume strength training(CST) and ergometer-based high-intensity interval training (HIIT).~CST: Conventional 1-set strength training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum.~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. 2 exercise sessions per week. Order of application: CST - HIIT. Additionally, participants receive individualized nutritional counseling.
Study NCT03882424 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRS003
Description: 25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
Study NCT03882424 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: China-approved Bevacizumab
Description: 25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
Study NCT03882424 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed Avastin
Description: 25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
Study NCT00947284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine plus naloxone
Description: single dose administered intravenously
Study NCT00947284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine plus saline
Description: single dose administered intravenously
Study NCT00947284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naloxone plus saline
Description: single dose administered intravenously
Study NCT04172285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Home-based physical activity program
Study NCT04172285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Physical activity and supplementation
Description: Home-based physical activity program and amminoacid supplementation
Study NCT04172285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No intervention
Study NCT01417754 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Toremifene
Description: 20mg toremifene per day in tablet form starting from the cycle day 15 and continued to premenstrual period. Medication using about 10 days per volunteer
Study NCT01953744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Fluconazole is presented in 150mg capsules and will be administered by oral route at a dosage of 6-8mg/kg/day during 28 days.
Study NCT01953744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meglumine Antimoniate
Description: Meglumine Antimoniate will be administered as the standard treatment for cutaneous leishmaniasis by intravenous route at a dosage of 20mg/kg/day, during 20 days.
Study NCT03404999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical decision support
Description: Decision support system (see description of hypertension decision support system alerts and order sets for details)
Study NCT02427113 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sound Oasis Vibrating Chair
Description: Sound oasis vibroacoustic chair will be used as treatment for managing TMD related pain
Study NCT02427113 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Select Music
Description: The self-select music of the participants will be applied for managing the painful symptoms of TMD
Study NCT03839108 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paraffin wax
Description: Paraffin group patients will be told to take of jewellery and dip their hands into the bath of melted wax (52 ºC) with hands open and hand wrist in neutral position for 10 times .In paraffin wax group, patients will be treated 5 days a week for 2 weeks period. Paraffin wax bath will be applied for 20 minutes in every physical therapy session.
Study NCT03839108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolotherapy
Description: . Prolotherapy is a nonsurgical regenerative injection technique that introduces small amounts of an irritant solution to the site of painful and degenerated tendon insertions (entheses), joints, ligaments, and in adjacent joint spaces during several treatment sessions to promote growth of normal cells and tissues.Hypertonic dextrose solution is most common used agent. In prolotheraphy group, %15 dextrose solution will be applied to medial and lateral aspect of proximal interphalangeal joints (PIJ), distal interphalangeal joints and carpometacarpal joint of thumb for 3 sessions once a week period
Study NCT02432352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Our Family Our Future
Description: The Our Family Our Future Program is a family preventive intervention that uses resilience and prevention focused strategies to reduce sexual risk behaviors and build mental wellbeing among adolescents.
Study NCT04130308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retrun to run protocol
Description: Progressive return to run protocol for patients after ACL-R
Study NCT00566384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dehydroepiandrosterone, BAY86-5314
Description: Treatment with daily oral intake of two capsules containing 50 mg DHEA each. Treatment duration will be 24 weeks
Study NCT02830386 — intervention group
Intervention type: DEVICE
Intervention: LVIS stent
Description: Patients who meet the inclusion criteria will be treated with a low profile visualized intraluminal support (LVIS) stent with coils.
Study NCT02950792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViewRay MRI
Description: ViewRay Magnetic Resonance Imaging
Study NCT02950792 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy Boost
Description: In the (week 5), all patients will have a week 5 MRI and Four-dimensional computed tomography (4D CT) for purposes of planning Phase II boost. Gross tumors \< 5 cm will receive a MR-based adaptive replanning Stereo boost of 80 Gy - 90 Gy (20 Gy-30 Gy in 5 fractions). Gross tumors \< 5cm will receive an MR-based adaptive replan fractionated boost to 74 Gy at 2.4 Gy/day. Individualized radiation therapy prescription to primary tumor will maintain organs at risk (OAR) constraints to lung including mean lung dose (MLD) \< 20 Gy with V20 \< 37%. Simultaneously, MRI-based adaptive replanning boost of 12 Gy in 5 fractions (2.4 Gy/day) will be given to gross lymph nodes. Final doses prescribed will be limited by doses to all OARs.
Study NCT01598376 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 7/0 vicryl suture
Description: 7/0 vicryl test suture placed as one of 3 everting sutures
Study NCT01598376 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 5/0 vicryl test suture
Description: 5/0 vicryl test suture placed as one of 3 everting sutures
Study NCT01672931 — intervention group
Intervention type: OTHER
Intervention: Oocyte Measurement
Study NCT02717390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bright By Three (BB3)
Description: The purpose of the BB3 intervention (annual home visit, written materials, and BB3 mobile application 'app') is to increase parental talking, reading, playing, and praise (TRPP) behaviors and improves children's social-emotional and language development at ages 2, 3, and 4 years.